title: Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.
abstract: Antibiotic-induced changes in the intestinal microbiota predispose mammalian hosts to infection with antibiotic-resistant pathogens. Clostridium difficile is a Gram-positive intestinal pathogen that causes colitis and diarrhea in patients following antibiotic treatment. Clindamycin predisposes patients to C. difficile colitis. Here, we have used Roche-454 16S rRNA gene pyrosequencing to longitudinally characterize the intestinal microbiota of mice following clindamycin treatment in the presence or absence of C. difficile infection. We show that a single dose of clindamycin markedly reduces the diversity of the intestinal microbiota for at least 28 days, with an enduring loss of ca. 90% of normal microbial taxa from the cecum. Loss of microbial complexity results in dramatic sequential expansion and contraction of a subset of bacterial taxa that are minor contributors to the microbial consortium prior to antibiotic treatment. Inoculation of clindamycin-treated mice with C. difficile (VPI 10463) spores results in rapid development of diarrhea and colitis, with a 4- to 5-day period of profound weight loss and an associated 40 to 50% mortality rate. Recovering mice resolve diarrhea and regain weight but remain highly infected with toxin-producing vegetative C. difficile bacteria and, in comparison to the acute stage of infection, have persistent, albeit ameliorated cecal and colonic inflammation. The microbiota of "recovered" mice remains highly restricted, and mice remain susceptible to C. difficile infection at least 10 days following clindamycin, suggesting that resolution of diarrhea and weight gain may result from the activation of mucosal immune defenses.
authors: Infectious Diseases Service, Department of Medicine, Lucille Castori Center for Microbes, Inflammation and Cancer, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
authors: Charlie G
authors: CG
authors: Buffie
authors: Irene
authors: I
authors: Jarchum
authors: Michele
authors: M
authors: Equinda
authors: Lauren
authors: L
authors: Lipuma
authors: Asia
authors: A
authors: Gobourne
authors: Agnes
authors: A
authors: Viale
authors: Carles
authors: C
authors: Ubeda
authors: Joao
authors: J
authors: Xavier
authors: Eric G
authors: EG
authors: Pamer
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D044822:Biodiversity; D002981:Clindamycin / Q000008:administration & dosage*; D016360:Clostridioides difficile / Q000472:pathogenicity; D003015:Clostridium Infections / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D003092:Colitis / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D003967:Diarrhea / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D004198:Disease Susceptibility; D005260:Female; D041981:Gastrointestinal Tract / Q000378:metabolism*; D008137:Longitudinal Studies; D051379:Mice; D008810:Mice, Inbred C57BL; D017422:Sequence Analysis, DNA / Q000379:methods; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin